Replies to post #162066 on Biotech Values

[imnot6]

Because Otamixaban still has potential as an alternative to Coumadin for complications from atrial fib.

[genisi]

Quiz (low difficulty): Why did SNY take a writeoff for the failure of Iniparib (#msg-88593358) but not for the failure of Otamixaban (#msg-88592744)?

Because Sanofi got Iniparib through the 2009 purchase of BiPar Sciences Inc., while Otamixaban was discovered and developed in-house.